- Home
- CTNM vs LUCD Comparison
CTNM vs LUCD Comparison
Compare CTNM & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- LUCD
- Stock Information
- Founded
- CTNM 2009
- LUCD 2018
- Country
- CTNM United States
- LUCD United States
- Employees
- CTNM N/A
- LUCD N/A
- Industry
- CTNM
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CTNM
- LUCD Health Care
- Exchange
- CTNM Nasdaq
- LUCD Nasdaq
- Market Cap
- CTNM 114.1M
- LUCD 135.6M
- IPO Year
- CTNM 2024
- LUCD 2021
- Fundamental
- Price
- CTNM $3.87
- LUCD $1.13
- Analyst Decision
- CTNM Strong Buy
- LUCD Strong Buy
- Analyst Count
- CTNM 4
- LUCD 4
- Target Price
- CTNM $23.75
- LUCD $3.88
- AVG Volume (30 Days)
- CTNM 86.8K
- LUCD 961.7K
- Earning Date
- CTNM 05-16-2025
- LUCD 05-14-2025
- Dividend Yield
- CTNM N/A
- LUCD N/A
- EPS Growth
- CTNM N/A
- LUCD N/A
- EPS
- CTNM N/A
- LUCD N/A
- Revenue
- CTNM N/A
- LUCD $4,346,000.00
- Revenue This Year
- CTNM N/A
- LUCD $107.75
- Revenue Next Year
- CTNM N/A
- LUCD $231.37
- P/E Ratio
- CTNM N/A
- LUCD N/A
- Revenue Growth
- CTNM N/A
- LUCD 79.00
- 52 Week Low
- CTNM $3.69
- LUCD $0.63
- 52 Week High
- CTNM $22.00
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- LUCD 36.90
- Support Level
- CTNM N/A
- LUCD $1.19
- Resistance Level
- CTNM N/A
- LUCD $1.24
- Average True Range (ATR)
- CTNM 0.00
- LUCD 0.07
- MACD
- CTNM 0.00
- LUCD -0.01
- Stochastic Oscillator
- CTNM 0.00
- LUCD 4.17
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.